Diagnostic and prognostic molecular biomarkers for prostate cancer

Histopathology

Volumn 60, Issue 1, 2012, Pages 125-141

  Kristiansen, Glen ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Diagnostic marker; Molecular biology; Prognostic marker; Prostate cancer

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ANDROGEN; ANDROGEN RECEPTOR; APC PROTEIN; CYTOCHROME C; FATTY ACID SYNTHASE; GLUTATHIONE TRANSFERASE P1; GOLM1 PROTEIN; HOMEODOMAIN PROTEIN; HOX PROTEIN; I KAPPA B KINASE INHIBITOR; KI 67 ANTIGEN; MESSENGER RNA; MICRORNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTEIN; PROTEIN NKX3.1; PROTEIN P53; PROTEIN P63; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR PITX2; TUMOR MARKER; UNCLASSIFIED DRUG;

ANDROGEN THERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SCREENING; COMPARATIVE GENOMIC HYBRIDIZATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE TRANSLOCATION; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR DIAGNOSIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR ABLATION; UPREGULATION;

HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84255162948     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04083.x     Document Type: Review

References (219)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 2011; 61; 69-90.
2. Egevad L, Allsbrook WC Jr, Epstein JI. Current practice of diagnosis and reporting of prostate cancer on needle biopsy among genitourinary pathologists. Hum. Pathol. 2006; 37; 292-297.
3. Galanina N, Bossuyt V, Harris LN. Molecular predictors of response to therapy for breast cancer. Cancer J. 2011; 17; 96-103.
4. Linardou H, Dahabreh IJ, Kanaloupiti D et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008; 9; 962-972.
5. Winder T, Lenz HJ. Molecular predictive and prognostic markers in colon cancer. Cancer Treat. Rev. 2010; 36; 550-556.
6. Dadras SS. Molecular diagnostics in melanoma: current status and perspectives. Arch. Pathol. Lab. Med. 2011; 135; 860-869.
7. Totten RS, Heinemann MW, Hudson PB, Sproul EE, Stout AP. Microscopic differential diagnosis of latent carcinoma of prostate. AMA Arch. Pathol. 1953; 55; 131-141.
8. Thorson P, Humphrey PA. Minimal adenocarcinoma in prostate needle biopsy tissue. Am. J. Clin. Pathol. 2000; 114; 896-909.
9. Epstein JI. Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Mod. Pathol. 2004; 17; 307-315.
10. Brawer MK, Peehl DM, Stamey TA, Bostwick DG. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res. 1985; 45; 3663-3667.
11. Hedrick L, Epstein JI. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am. J. Surg. Pathol. 1989; 13; 389-396.
12. Signoretti S, Waltregny D, Dilks J et al. p63 is a prostate basal cell marker and is required for prostate development. Am. J. Pathol. 2000; 157; 1769-1775.
13. Weinstein MH, Signoretti S, Loda M. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod. Pathol. 2002; 15; 1302-1308.
14. Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am. J. Surg. Pathol. 2002; 26; 1161-1168.
15. Zhou M, Shah R, Shen R, Rubin MA. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells. Am. J. Surg. Pathol. 2003; 27; 365-371.
16. Oliai BR, Kahane H, Epstein JI. Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody. Am. J. Surg. Pathol. 2002; 26; 1151-1160.
17. Ali TZ, Epstein JI. False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells. Am. J. Surg. Pathol. 2008; 32; 1890-1895.
18. Osunkoya AO, Hansel DE, Sun X, Netto GJ, Epstein JI. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Am. J. Surg. Pathol. 2008; 32; 461-467.
19. Kuroda N, Katto K, Tamura M et al. Immunohistochemical application of D2-40 as basal cell marker in evaluating atypical small acinar proliferation of initial routine prostatic needle biopsy materials. Med. Mol. Morphol. 2010; 43; 165-169.
20. Hasegawa M, Hagiwara S, Sato T et al. CD109, a new marker for myoepithelial cells of mammary, salivary, and lacrimal glands and prostate basal cells. Pathol. Int. 2007; 57; 245-250.
21. Jarrard DF, Paul R, van Bokhoven A et al. P-Cadherin is a basal cell-specific epithelial marker that is not expressed in prostate cancer. Clin. Cancer Res. 1997; 3; 2121-2128.
22. Ramos Soler D, Mayordomo Aranda E, Calatayud Blas A, Rubio Briones J, Solsona Narbon E, Llombart Bosch A. Usefulness of bcl-2 expression as a new basal cell marker in prostatic pathology. Actas Urol. Esp. 2006; 30; 345-352.
23. Beckett ML, Wright GL Jr. Characterization of a prostate carcinoma mucin-like antigen (PMA). Int. J. Cancer 1995; 62; 703-710.
24. Beckett ML, Lipford GB, Haley CL, Schellhammer PF, Wright GL Jr. Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas. Cancer Res. 1991; 51; 1326-1333.
25. Xu J, Stolk JA, Zhang X et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res. 2000; 60; 1677-1682.
26. Jiang Z, Woda BA, Rock KL et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am. J. Surg. Pathol. 2001; 25; 1397-1404.
27. Rubin MA, Zhou M, Dhanasekaran SM et al. Alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002; 287; 1662-1670.
28. Kunju LP, Chinnaiyan AM, Shah RB. Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer. Histopathology 2005; 47; 587-596.
29. Luo J, Zha S, Gage WR et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002; 62; 2220-2226.
30. Lloyd MD, Darley DJ, Wierzbicki AS, Threadgill MD. Alpha-methylacyl-CoA racemase - an 'obscure' metabolic enzyme takes centre stage. FEBS J. 2008; 275; 1089-1102.
31. Went PT, Sauter G, Oberholzer M, Bubendorf L. Abundant expression of AMACR in many distinct tumour types. Pathology 2006; 38; 426-432.
32. Dorer R, Odze RD. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease. Am. J. Surg. Pathol. 2006; 30; 871-877.
33. Sonwalkar SA, Rotimi O, Scott N et al. A study of indefinite for dysplasia in Barrett's oesophagus: reproducibility of diagnosis, clinical outcomes and predicting progression with AMACR (alpha-methylacyl-CoA-racemase). Histopathology 2010; 56; 900-907.
34. Carswell BM, Woda BA, Wang X, Li C, Dresser K, Jiang Z. Detection of prostate cancer by alpha-methylacyl CoA racemase (P504S) in needle biopsy specimens previously reported as negative for malignancy. Histopathology 2006; 48; 668-673.
35. Farinola MA, Epstein JI. Utility of immunohistochemistry for alpha-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy. Hum. Pathol. 2004; 35; 1272-1278.
36. Herawi M, Epstein JI. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate. Am. J. Surg. Pathol. 2007; 31; 889-894.
37. Jiang Z, Wu CL, Woda BA et al. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker. Histopathology 2004; 45; 218-225.
38. Zhou M, Aydin H, Kanane H, Epstein JI. How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers? Am. J. Surg. Pathol. 2004; 28; 239-243.
39. Paner GP, Luthringer DJ, Amin MB. Best practice in diagnostic immunohistochemistry: prostate carcinoma and its mimics in needle core biopsies. Arch. Pathol. Lab. Med. 2008; 132; 1388-1396.
40. Jiang Z, Iczkowski KA, Woda BA, Tretiakova M, Yang XJ. P504S immunostaining boosts diagnostic resolution of 'suspicious' foci in prostatic needle biopsy specimens. Am. J. Clin. Pathol. 2004; 121; 99-107.
41. Herawi M, Parwani AV, Irie J, Epstein JI. Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion. Am. J. Surg. Pathol. 2005; 29; 874-880.
42. Wang W, Sun X, Epstein JI. Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study. Am. J. Surg. Pathol. 2008; 32; 851-857.
43. Murphy AJ, Hughes CA, Lannigan G, Sheils O, O'Leary J, Loftus B. Heterogeneous expression of alpha-methylacyl-CoA racemase in prostatic cancer correlates with Gleason score. Histopathology 2007; 50; 243-251.
44. Gologan A, Bastacky S, McHale T et al. Age-associated changes in alpha-methyl CoA racemase (AMACR) expression in nonneoplastic prostatic tissues. Am. J. Surg. Pathol. 2005; 29; 1435-1441.
45. Kristiansen G, Fritzsche FR, Wassermann K et al. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br. J. Cancer 2008; 99; 939-948.
46. Ananthanarayanan V, Deaton RJ, Yang XJ, Pins MR, Gann PH. Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer. Prostate 2005; 63; 341-346.
47. Wu CL, Yang XJ, Tretiakova M et al. Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia. Hum. Pathol. 2004; 35; 1008-1013.
48. Bachert C, Fimmel C, Linstedt AD. Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic 2007; 8; 1415-1423.
49. Iftikhar R, Kladney RD, Havlioglu N et al. Disease- and cell-specific expression of GP73 in human liver disease. Am. J. Gastroenterol. 2004; 99; 1087-1095.
50. Kladney RD, Bulla GA, Guo L et al. GP73, a novel Golgi-localized protein upregulated by viral infection. Gene 2000; 249; 53-65.
51. Kladney RD, Cui X, Bulla GA, Brunt EM, Fimmel CJ. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology 2002; 35; 1431-1440.
52. Marrero JA, Romano PR, Nikolaeva O et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J. Hepatol. 2005; 43; 1007-1012.
53. Luo JH, Yu YP, Cieply K et al. Gene expression analysis of prostate cancers. Mol. Carcinog. 2002; 33; 25-35.
54. Lapointe J, Li C, Higgins JP et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl Acad. Sci. USA 2004; 101; 811-816.
55. Kristiansen G, Pilarsky C, Wissmann C et al. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J. Pathol. 2005; 205; 359-376.
56. Wei S, Dunn TA, Isaacs WB, De Marzo AM, Luo J. GOLPH2 and MYO6: putative prostate cancer markers localized to the golgi apparatus. Prostate 2008; 68; 1387-1395.
57. Varambally S, Laxman B, Mehra R et al. Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. Neoplasia 2008; 10; 1285-1294.
58. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 2007; 7; 763-777.
59. Warburg O. On the origin of cancer cells. Science 1956; 123; 309-314.
60. Prowatke I, Devens F, Benner A et al. Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays. Br. J. Cancer 2007; 96; 82-88.
61. Shurbaji MS, Kalbfleisch JH, Thurmond TS. Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum. Pathol. 1996; 27; 917-921.
62. Baron A, Migita T, Tang D, Loda M. Fatty acid synthase: a metabolic oncogene in prostate cancer? J. Cell. Biochem. 2004; 91; 47-53.
63. Fiorentino M, Zadra G, Palescandolo E et al. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab. Invest. 2008; 88; 1340-1348.
64. Migita T, Ruiz S, Fornari A et al. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J. Natl Cancer Inst. 2009; 101; 519-532.
65. Rossi S, Graner E, Febbo P et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol. Cancer Res. 2003; 1; 707-715.
66. Tischler V, Fritzsche FR, Gerhardt J et al. Comparison of the diagnostic value of fatty acid synthase (FASN) with alpha-methylacyl-CoA racemase (AMACR) as prostatic cancer tissue marker. Histopathology 2010; 56; 811-815.
67. Wu X, Zayzafoon M, Zhang X, Hameed O. Is there a role for fatty acid synthase in the diagnosis of prostatic adenocarcinoma?: a comparison with AMACR. Am. J. Clin. Pathol. 2011; 136; 239-246.
68. Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310; 644-648.
69. Demichelis F, Fall K, Perner S et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007; 26; 4596-4599.
70. Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat. Rev. Urol. 2009; 6; 429-439.
71. Park K, Tomlins SA, Mudaliar KM et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010; 12; 590-598.
72. Miettinen M, Wang ZF, Paetau A et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am. J. Surg. Pathol. 2011; 35; 432-441.
73. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res. 2006; 66; 8347-8351.
74. van Leenders GJ, Boormans JL, Vissers CJ et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod. Pathol. 2011; 24; 1128-1138.
75. Falzarano SM, Zhou M, Carver P et al. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch. 2011; 459; 441-447.
76. Chaux A, Albadine R, Toubaji A et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am. J. Surg. Pathol. 2011; 35; 1014-1020.
77. He H, Magi-Galluzzi C, Li J et al. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with 'atypical glands suspicious for cancer'. Am. J. Surg. Pathol. 2011; 35; 608-614.
78. Yaskiv O, Zhang X, Simmerman K et al. The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am. J. Surg. Pathol. 2011; 35; 1062-1068.
79. Lapointe J, Li C, Giacomini CP et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res. 2007; 67; 8504-8510.
80. Braun M, Scheble VJ, Menon R et al. Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer. Histopathology 2011; 58; 1028-1036.
81. Mosquera JM, Perner S, Demichelis F et al. Morphological features of TMPRSS2-ERG gene fusion prostate cancer. J. Pathol. 2007; 212; 91-101.
82. Fine SW, Gopalan A, Leversha MA et al. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod. Pathol. 2010; 23; 1325-1333.
83. Guo CC, Zuo G, Cao D, Troncoso P, Czerniak BA. Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion. Mod. Pathol. 2009; 22; 866-871.
84. Bismar TA, Trpkov K. TMPRSS2-ERG gene fusion in transition zone prostate cancer. Mod. Pathol. 2010; 23; 1040-1041; author reply 1041-1042.
85. Falzarano SM, Navas M, Simmerman K et al. ERG rearrangement is present in a subset of transition zone prostatic tumors. Mod. Pathol. 2010; 23; 1499-1506.
86. Mao X, Yu Y, Boyd LK et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res. 2010; 70; 5207-5212.
87. Miyagi Y, Sasaki T, Fujinami K et al. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Mod. Pathol. 2010; 23; 1492-1498.
88. Magi-Galluzzi C, Tsusuki T, Elson P et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 2011; 71; 489-497.
89. Mosquera JM, Perner S, Genega EM et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin. Cancer Res. 2008; 14; 3380-3385.
90. Perner S, Mosquera JM, Demichelis F et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am. J. Surg. Pathol. 2007; 31; 882-888.
91. Haggarth L, Hagglof C, Jaraj SJ et al. Diagnostic biomarkers of prostate cancer. Scand. J. Urol. Nephrol. 2011; 45; 60-67.
92. Petraki CD, Sfikas CP. Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma. Histol. Histopathol. 2007; 22; 107-118.
93. Bostwick DG. Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer. Am. J. Clin. Pathol. 1994; 102; S31-S37.
94. Kraus TS, Cohen C, Siddiqui MT. Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma. Diagn. Pathol. 2010; 5; 63.
95. Alanen KA, Kuopio T, Koskinen PJ, Nevalainen TJ. Immunohistochemical labelling for prostate specific antigen in non-prostatic tissues. Pathol. Res. Pract. 1996; 192; 233-237.
96. van Krieken JH. Prostate marker immunoreactivity in salivary gland neoplasms. A rare pitfall in immunohistochemistry. Am. J. Surg. Pathol. 1993; 17; 410-414.
97. Renshaw AA, Granter SR. Metastatic, sarcomatoid, and PSA- and PAP-negative prostatic carcinoma: diagnosis by fine-needle aspiration. Diagn. Cytopathol. 2000; 23; 199-201.
98. Wright GL Jr, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol. Oncol. 1995; 1; 18-28.
99. Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int. J. Cancer 1995; 62; 552-558.
100. Kinoshita Y, Kuratsukuri K, Landas S et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J. Surg. 2006; 30; 628-636.
101. Samplaski MK, Heston W, Elson P, Magi-Galluzzi C, Hansel DE. Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature. Mod. Pathol. 2011; 24; 1521-1529.
102. Fleischmann A, Rocha C, Schobinger S, Seiler R, Wiese B, Thalmann GN. Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases. Prostate 2011; 71; 453-460.
103. Loda M, Fogt F, French FS et al. Androgen receptor immunohistochemistry on paraffin-embedded tissue. Mod. Pathol. 1994; 7; 388-391.
104. Jaspers HC, Verbist BM, Schoffelen R et al. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J. Clin. Oncol. 2011; 29; e473-e476.
105. Murphy CE, Carder PJ, Lansdown MR, Speirs V. Steroid hormone receptor expression in male breast cancer. Eur. J. Surg. Oncol. 2006; 32; 44-47.
106. Xu J, Kalos M, Stolk JA et al. Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res. 2001; 61; 1563-1568.
107. Kalos M, Askaa J, Hylander BL et al. Prostein expression is highly restricted to normal and malignant prostate tissues. Prostate 2004; 60; 246-256.
108. Sheridan T, Herawi M, Epstein JI, Illei PB. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Am. J. Surg. Pathol. 2007; 31; 1351-1355.
109. Osunkoya AO, Netto GJ, Epstein JI. Colorectal adenocarcinoma involving the prostate: report of 9 cases. Hum. Pathol. 2007; 38; 1836-1841.
110. Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am. J. Surg. Pathol. 2007; 31; 1246-1255.
111. Lane Z, Hansel DE, Epstein JI. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder. Am. J. Surg. Pathol. 2008; 32; 1322-1326.
112. Lane Z, Epstein JI, Ayub S, Netto GJ. Prostatic adenocarcinoma in colorectal biopsy: clinical and pathologic features. Hum. Pathol. 2008; 39; 543-549.
113. Srinivasan M, Parwani AV. Diagnostic utility of p63/P501S double sequential immunohistochemical staining in differentiating urothelial carcinoma from prostate carcinoma. Diagn. Pathol. 2011; 6; 67.
114. Scheble VJ, Braun M, Beroukhim R et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod. Pathol. 2010; 23; 1061-1067.
115. Perner S, Svensson MA, Hossain RR et al. ERG rearrangement metastasis patterns in locally advanced prostate cancer. Urology 2010; 75; 762-767.
116. Scheble VJ, Braun M, Wilbertz T et al. ERG rearrangement in small cell prostatic and lung cancer. Histopathology 2010; 56; 937-943.
117. Guo CC, Dancer JY, Wang Y et al. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum. Pathol. 2011; 42; 11-17.
118. Williamson SR, Zhang S, Yao JL et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod. Pathol. 2011; 24; 1120-1127.
119. Lotan TL, Gupta NS, Wang W et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod. Pathol. 2011; 24; 820-828.
120. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am. J. Surg. Pathol. 2008; 32; 65-71.
121. Voeller HJ, Augustus M, Madike V, Bova GS, Carter KC, Gelmann EP. Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res. 1997; 57; 4455-4459.
122. He WW, Sciavolino PJ, Wing J et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 1997; 43; 69-77.
123. Gelmann EP, Bowen C, Bubendorf L. Expression of NKX3.1 in normal and malignant tissues. Prostate 2003; 55; 111-117.
124. Bethel CR, Faith D, Li X et al. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with Gleason score and chromosome 8p deletion. Cancer Res. 2006; 66; 10683-10690.
125. Bowen C, Bubendorf L, Voeller HJ et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res. 2000; 60; 6111-6115.
126. Gurel B, Ali TZ, Montgomery EA et al. NKX3.1 as a marker of prostatic origin in metastatic tumors. Am. J. Surg. Pathol. 2010; 34; 1097-1105.
127. Nam RK, Kattan MW, Chin JL et al. Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J. Clin. Oncol. 2011; 29; 2959-2964.
128. Shariat SF, Kattan MW, Vickers AJ, Karakiewicz PI, Scardino PT. Critical review of prostate cancer predictive tools. Future Oncol. 2009; 5; 1555-1584.
129. Klotz L. Active surveillance for favorable risk prostate cancer: what are the results, and how safe is it? Semin. Radiat. Oncol. 2008; 18; 2-6.
130. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280; 975-980.
131. Chodak GW, Thisted RA, Gerber GS et al. Results of conservative management of clinically localized prostate cancer. N. Engl. J. Med. 1994; 330; 242-248.
132. Harlan SR, Cooperberg MR, Elkin EP et al. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J. Urol. 2003; 170; 1804-1807.
133. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293; 2095-2101.
134. Lein M, Stibane I, Mansour R et al. Complications, urinary continence, and oncologic outcome of 1000 laparoscopic transperitoneal radical prostatectomies - experience at the Charite Hospital Berlin, Campus Mitte. Eur. Urol. 2006; 50; 1278-1282; discussion 1283-1274.
135. Dall'Era MA, Cooperberg MR, Chan JM et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 2008; 112; 1650-1659.
136. Harnden P, Naylor B, Shelley MD, Clements H, Coles B, Mason MD. The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta-analysis. Cancer 2008; 112; 971-981.
137. Klotz L. Active surveillance for favorable risk prostate cancer: rationale, risks, and results. Urol. Oncol. 2007; 25; 505-509.
138. Loeb S, Roehl KA, Thaxton CS, Catalona WJ. Combined prostate-specific antigen density and biopsy features to predict 'clinically insignificant' prostate cancer. Urology 2008; 72; 143-147.
139. Jeldres C, Suardi N, Walz J et al. Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men. Eur. Urol. 2008; 54; 1306-1313.
140. van Oort IM, Kok DE, Kiemeney LA, Hulsbergen-van de Kaa CA, Witjes JA. A single institution experience with biochemical recurrence after radical prostatectomy for tumors that on pathology are of small volume or 'insignificant'. Urol. Oncol. 2009; 27; 509-513.
141. Sengupta S, Blute ML, Bagniewski SM et al. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer. BJU Int. 2008; 101; 170-174.
142. Chun FK, Haese A, Ahyai SA et al. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer 2008; 113; 701-709.
143. Stamatiou K, Alevizos A, Mariolis A et al. Do clinically insignificant tumors of the prostate exist? Urol. Int. 2008; 81; 379-382.
144. Perner S, Demichelis F, Beroukhim R et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006; 66; 8337-8341.
145. Nam RK, Sugar L, Wang Z et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol. Ther. 2007; 6; 40-45.
146. Nam RK, Sugar L, Yang W et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br. J. Cancer 2007; 97; 1690-1695.
147. Attard G, Clark J, Ambroisine L et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008; 27; 253-263.
148. Yoshimoto M, Joshua AM, Cunha IW et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod. Pathol. 2008; 21; 1451-1460.
149. Sboner A, Demichelis F, Calza S et al. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med. Genomics 2010; 3; 8.
150. Winnes M, Lissbrant E, Damber JE, Stenman G. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol. Rep. 2007; 17; 1033-1036.
151. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin. Cancer Res. 2008; 14; 3395-3400.
152. Boormans JL, Porkka K, Visakorpi T, Trapman J. Confirmation of the association of TMPRSS2(exon 0): ERG expression and a favorable prognosis of primary prostate cancer. Eur. Urol. 2011; 60; 183-184.
153. Hermans KG, Boormans JL, Gasi D et al. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin. Cancer Res. 2009; 15; 6398-6403.
154. Furusato B, Gao CL, Ravindranath L et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod. Pathol. 2008; 21; 67-75.
155. FitzGerald LM, Agalliu I, Johnson K et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer 2008; 8; 230.
156. Esgueva R, Perner S, LaFargue C et al. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod. Pathol. 2010; 23; 539-546.
157. Gopalan A, Leversha MA, Satagopan JM et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res. 2009; 69; 1400-1406.
158. Minner S, Enodien M, Sirma H et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of anti-hormonal therapy. Clin. Cancer Res. 2011; 17; 5878-5888.
159. Toubaji A, Albadine R, Meeker AK et al. Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Mod. Pathol. 2011; 24; 1511-1520.
160. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J. Urol. 2003; 170; 1872-1876.
161. Carver BS, Bianco FJ Jr, Scardino PT, Eastham JA. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J. Urol. 2006; 176; 564-568.
162. Porter CR, Kodama K, Gibbons RP et al. 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. J. Urol. 2006; 176; 569-574.
163. Lee SE, Currin SM, Paulson DF, Walther PJ. Flow cytometric determination of ploidy in prostatic adenocarcinoma: a comparison with seminal vesicle involvement and histopathological grading as a predictor of clinical recurrence. J. Urol. 1988; 140; 769-774.
164. Stephenson RA, James BC, Gay H, Fair WR, Whitmore WF Jr, Melamed MR. Flow cytometry of prostate cancer: relationship of DNA content to survival. Cancer Res. 1987; 47; 2504-2507.
165. Frankfurt OS, Chin JL, Englander LS, Greco WR, Pontes JE, Rustum YM. Relationship between DNA ploidy, glandular differentiation, and tumor spread in human prostate cancer. Cancer Res. 1985; 45; 1418-1423.
166. Berger MF, Lawrence MS, Demichelis F et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470; 214-220.
167. Jeronimo C, Bastian PJ, Bjartell A et al. Epigenetics in prostate cancer: biologic and clinical relevance. Eur. Urol. 2011; 60; 753-766.
168. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128; 683-692.
169. Lin X, Tascilar M, Lee WH et al. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am. J. Pathol. 2001; 159; 1815-1826.
170. Jeronimo C, Henrique R, Hoque MO et al. Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin. Cancer Res. 2004; 10; 4010-4014.
171. Henrique R, Ribeiro FR, Fonseca D et al. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin. Cancer Res. 2007; 13; 6122-6129.
172. Weiss G, Cottrell S, Distler J et al. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J. Urol. 2009; 181; 1678-1685.
173. Liu L, Kron KJ, Pethe VV et al. Association of tissue promoter methylation levels of APC, TGFbeta2, HOXD3, and RASSF1A with prostate cancer progression. Int. J. Cancer 2011; 129; 2454-2462.
174. Kron KJ, Liu L, Pethe VV et al. DNA methylation of HOXD3 as a marker of prostate cancer progression. Lab. Invest. 2010; 90; 1060-1067.
175. Banez LL, Sun L, van Leenders GJ et al. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J. Urol. 2010; 184; 149-156.
176. Schatz P, Dietrich D, Koenig T et al. Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylation. J. Mol. Diagn. 2010; 12; 345-353.
177. Vinarskaja A, Schulz WA, Ingenwerth M, Hader C, Arsov C. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis. Urol. Oncol. 2011; [Epub ahead of print] DOI: org/10.1016/j.urolonc.2011.04.010.
178. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J. Clin. Oncol. 2009; 27; 5848-5856.
179. Schaefer A, Jung M, Mollenkopf HJ et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int. J. Cancer 2010; 126; 1166-1176.
180. Leite KR, Tomiyama A, Reis ST et al. MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J. Urol. 2011; 185; 1118-1122.
181. Spahn M, Kneitz S, Scholz CJ et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int. J. Cancer 2010; 127; 394-403.
182. Martens-Uzunova ES, Jalava SE, Dits NF et al. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 2011; [Epub ahead of print] DOI: 10.1038/onc.2011.304.
183. Dhanasekaran SM, Barrette TR, Ghosh D et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412; 822-826.
184. Varambally S, Dhanasekaran SM, Zhou M et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419; 624-629.
185. Henshall SM, Afar DE, Hiller J et al. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 2003; 63; 4196-4203.
186. Singh D, Febbo PG, Ross K et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002; 1; 203-209.
187. Latil A, Bieche I, Chene L et al. Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior. Clin. Cancer Res. 2003; 9; 5477-5485.
188. Nanni S, Priolo C, Grasselli A et al. Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol. Cancer Res. 2006; 4; 79-92.
189. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J. Clin. Invest. 2004; 113; 913-923.
190. Varambally S, Yu J, Laxman B et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005; 8; 393-406.
191. Mucci LA, Pawitan Y, Demichelis F et al. Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort. Cancer Epidemiol. Biomarkers Prev. 2008; 17; 249-251.
192. Bismar TA, Demichelis F, Riva A et al. Defining aggressive prostate cancer using a 12-gene model. Neoplasia 2006; 8; 59-68.
193. Mucci LA, Pawitan Y, Demichelis F et al. Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol. Biomarkers Prev. 2008; 17; 1682-1688.
194. Cuzick J, Swanson GP, Fisher G et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011; 12; 245-255.
195. Chen JL, Li J, Stadler WM, Lussier YA. Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence. J. Am. Med. Inform. Assoc. 2011; 18; 392-402.
196. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144; 646-674.
197. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer 1983; 31; 13-20.
198. Stattin P, Damber JE, Karlberg L, Bergh A. Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer. J. Urol. 1997; 157; 219-222.
199. Borre M, Bentzen SM, Nerstrom B, Overgaard J. Tumor cell proliferation and survival in patients with prostate cancer followed expectantly. J. Urol. 1998; 159; 1609-1614.
200. Berney DM, Gopalan A, Kudahetti S et al. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br. J. Cancer 2009; 100; 888-893.
201. Bubendorf L, Sauter G, Moch H et al. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J. Pathol. 1996; 178; 437-441.
202. Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J. Urol. 1996; 156; 1064-1068.
203. Sebo TJ, Cheville JC, Riehle DL et al. Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. Am. J. Surg. Pathol. 2002; 26; 431-439.
204. Rubio J, Ramos D, Lopez-Guerrero JA et al. Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur. Urol. 2005; 48; 745-751.
205. Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TL, Visakorpi T. EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int. J. Cancer 2008; 122; 595-602.
206. Gunia S, Albrecht K, Koch S et al. Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability. World J. Urol. 2008; 26; 243-250.
207. Miyake H, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol. Oncol. 2010; 28; 145-151.
208. Khoo VS, Pollack A, Cowen D et al. Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate 1999; 41; 166-172.
209. Cowen D, Troncoso P, Khoo VS et al. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin. Cancer Res. 2002; 8; 1148-1154.
210. Pollack A, Cowen D, Troncoso P et al. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer 2003; 97; 1630-1638.
211. Pollack A, DeSilvio M, Khor LY et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J. Clin. Oncol. 2004; 22; 2133-2140.
212. Khor LY, Bae K, Paulus R et al. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J. Clin. Oncol. 2009; 27; 3177-3184.
213. Zellweger T, Gunther S, Zlobec I et al. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int. J. Cancer 2009; 124; 2116-2123.
214. Malhotra S, Lapointe J, Salari K et al. A tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancer. PLoS One 2011; 6; e20293.
215. Bubendorf L, Tapia C, Gasser TC et al. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum. Pathol. 1998; 29; 949-954.
216. Vis AN, Noordzij MA, Fitoz K, Wildhagen MF, Schroder FH, van der Kwast TH. Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J. Urol. 2000; 164; 2156-2161.
217. Rubin MA, Dunn R, Strawderman M, Pienta KJ. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am. J. Surg. Pathol. 2002; 26; 312-319.
218. Li R, Heydon K, Hammond ME et al. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin. Cancer Res. 2004; 10; 4118-4124.
219. Goto T, Nguyen BP, Nakano M, Ehara H, Yamamoto N, Deguchi T. Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population. Urology 2008; 72; 167-171.